Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Arrowhead Pharmaceuticals Inc shares valued at $3,123,349 were sold by O’Brien Patrick on Jan 05 ’26. At $63.11 per share, O’Brien Patrick sold 49,493 shares. The insider’s holdings dropped to 474,908 shares worth approximately $32.1 million following the completion of this transaction.
Also, Hamilton James C sold 40,164 shares, netting a total of over 2,534,661 in proceeds. Following the sale of shares at $63.11 each, the insider now holds 171,958 shares.
Before that, Anzalone Christopher Richard had sold 13,187 shares from its account. In a trade valued at $871,703, the Chief Executive Officer traded Arrowhead Pharmaceuticals Inc shares for $66.10 each. Upon closing the transaction, the insider’s holdings decreased to 13,187 shares, worth approximately $256.39 million.
As published in their initiating research note from Goldman on June 05, 2024, Arrowhead Pharmaceuticals Inc [ARWR] has been a Neutral and the price target has been revised to $31. Analysts at BofA Securities started covering the stock with ‘”a Buy”‘ outlook in a report released in early December. As of September 19, 2023, Citigroup has initiated its “Neutral” rating for ARWR. Earlier on July 21, 2023, TD Cowen initiated its rating. Their recommendation was “an Outperform” for ARWR stock.
Analyzing ARWR Stock Performance
On last trading session, Arrowhead Pharmaceuticals Inc [NASDAQ: ARWR] rose 3.55% to $67.6. The stock’s lowest price that day was $65.23, but it reached a high of $69.0 in the same session. During the last five days, there has been a surge of approximately 3.14%. Over the course of the year, Arrowhead Pharmaceuticals Inc shares have jumped approximately 245.60%.
Is Arrowhead Pharmaceuticals Inc subject to short interest?
Stocks of Arrowhead Pharmaceuticals Inc saw a sharp steep in short interest on 2025-12-31 dropping by -2.21 million shares to 9.63 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 11.84 million shares. A decline of -22.96% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.6 of the overall float, the days-to-cover ratio (short ratio) decline to 3.6.
Which companies own the most shares of Arrowhead Pharmaceuticals Inc (ARWR)?
In terms of Arrowhead Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 80.5 in the next 12 months, up nearly 23.31% from the previous closing price of $65.28. Analysts anticipate Arrowhead Pharmaceuticals Inc stock to reach 110 by 2026, with the lowest price target being 35. In spite of this, 9 analysts ranked Arrowhead Pharmaceuticals Inc stock as Buy at the end of 2026. On May 12, 2023, SVB Securities assigned a price target of “a Market perform” to the stock and downgraded coverage with a $40.
